A pig model of chronic hepatitis E displaying persistent viremia and a downregulation of innate immune responses in the liver.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
21
06
2023
accepted:
27
06
2023
medline:
9
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
epublish
Résumé
Hepatitis E virus (HEV) is a zoonotic virus transmitted by pig meat and responsible for chronic hepatitis E in immunocompromised patients. It has proved challenging to reproduce this disease in its natural reservoir. We therefore aimed to develop a pig model of chronic hepatitis E to improve the characterization of this disease. Ten pigs were treated with a tacrolimus-based regimen and intravenously inoculated with HEV. Tacrolimus trough concentration, HEV viremia, viral diversity, innate immune responses, liver histology, clinical disease and biochemical markers were monitored for 11 weeks post-infection (p.i.). HEV viremia persisted for 11 weeks p.i. HEV RNA was detected in the liver, small intestine, and colon at necropsy. Histological analysis revealed liver inflammation and fibrosis. Several mutations selected in the HEV genome were associated with compartmentalization in the feces and intestinal tissues, consistent with the hypothesis of extrahepatic replication in the digestive tract. Antiviral responses were characterized by a downregulation of IFN pathways in the liver, despite an upregulation of RIG-I and ISGs in the blood and liver. We developed a pig model of chronic hepatitis E that reproduced the major hallmarks of this disease. This model revealed a compartmentalization of HEV genomes in the digestive tract and a downregulation of innate immune responses in the liver. These original features highlight the relevance of our model for studies of the pathogenesis of chronic hepatitis E and for validating future treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis E virus (HEV) is a zoonotic virus transmitted by pig meat and responsible for chronic hepatitis E in immunocompromised patients. It has proved challenging to reproduce this disease in its natural reservoir. We therefore aimed to develop a pig model of chronic hepatitis E to improve the characterization of this disease.
METHODS
METHODS
Ten pigs were treated with a tacrolimus-based regimen and intravenously inoculated with HEV. Tacrolimus trough concentration, HEV viremia, viral diversity, innate immune responses, liver histology, clinical disease and biochemical markers were monitored for 11 weeks post-infection (p.i.).
RESULTS
RESULTS
HEV viremia persisted for 11 weeks p.i. HEV RNA was detected in the liver, small intestine, and colon at necropsy. Histological analysis revealed liver inflammation and fibrosis. Several mutations selected in the HEV genome were associated with compartmentalization in the feces and intestinal tissues, consistent with the hypothesis of extrahepatic replication in the digestive tract. Antiviral responses were characterized by a downregulation of IFN pathways in the liver, despite an upregulation of RIG-I and ISGs in the blood and liver.
CONCLUSIONS
CONCLUSIONS
We developed a pig model of chronic hepatitis E that reproduced the major hallmarks of this disease. This model revealed a compartmentalization of HEV genomes in the digestive tract and a downregulation of innate immune responses in the liver. These original features highlight the relevance of our model for studies of the pathogenesis of chronic hepatitis E and for validating future treatments.
Identifiants
pubmed: 37938097
doi: 10.1097/HC9.0000000000000274
pii: 02009842-202311010-00032
pmc: PMC10635601
pii:
doi:
Substances chimiques
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
Mod Pathol. 2021 Jan;34(1):233-248
pubmed: 32572157
J Clin Microbiol. 2001 Sep;39(9):3040-6
pubmed: 11526125
Proc Natl Acad Sci U S A. 2022 Jun 14;119(24):e2201862119
pubmed: 35671427
J Antimicrob Chemother. 2022 Jul 28;77(8):2300-2303
pubmed: 35534422
J Virol. 2016 Apr 14;90(9):4394-401
pubmed: 26889028
Int J Mol Sci. 2021 Aug 26;22(17):
pubmed: 34502167
J Clin Microbiol. 2001 Mar;39(3):918-23
pubmed: 11230404
Am J Transplant. 2009 Nov;9 Suppl 3:S1-155
pubmed: 19845597
BMC Vet Res. 2018 Dec 4;14(1):381
pubmed: 30514313
Front Microbiol. 2021 Jan 28;11:634430
pubmed: 33584599
J Clin Microbiol. 2012 Mar;50(3):897-902
pubmed: 22205792
N Engl J Med. 2007 Dec 20;357(25):2562-75
pubmed: 18094377
JHEP Rep. 2022 Aug 10;4(10):100546
pubmed: 36052220
Viruses. 2022 Jul 14;14(7):
pubmed: 35891516
Sci Rep. 2018 Jun 5;8(1):8585
pubmed: 29872132
Am J Transplant. 2008 Aug;8(8):1744-8
pubmed: 18557740
World J Gastroenterol. 2016 Aug 21;22(31):7030-45
pubmed: 27610014
PLoS One. 2014 Jun 17;9(6):e99861
pubmed: 24937350
Gut. 2017 May;66(5):920-929
pubmed: 27006186
Cell Tissue Res. 2020 May;380(2):287-304
pubmed: 32356014
J Gen Virol. 2019 Mar;100(3):471-483
pubmed: 30702423
Gastroenterology. 2011 May;140(5):1481-9
pubmed: 21354150
PLoS Pathog. 2017 May 30;13(5):e1006417
pubmed: 28558073
J Virol. 1998 Dec;72(12):9714-21
pubmed: 9811705
J Hepatol. 2016 Feb;64(2):433-485
pubmed: 26597456
Pharmacotherapy. 2022 Aug;42(8):599-633
pubmed: 36032031
Emerg Infect Dis. 2013 Apr;19(4):559-65
pubmed: 23628346
Br J Pharmacol. 2021 Sep;178(18):3829-3842
pubmed: 33974271
J Gen Virol. 2016 Mar;97(3):537-542
pubmed: 26743685
Liver Int. 2021 Dec;41(12):2866-2873
pubmed: 34392598
PLoS One. 2016 Dec 16;11(12):e0168577
pubmed: 27992534
J Hepatol. 2018 Jun;68(6):1256-1271
pubmed: 29609832
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1731-1741
pubmed: 31896581
Hepatology. 2018 Jun;67(6):2096-2112
pubmed: 29194722
Nat Methods. 2013 Nov;10(11):1048
pubmed: 24173380
Clin Infect Dis. 2015 Jan 1;60(1):96-9
pubmed: 25249523
Virology. 2023 Jan;578:128-140
pubmed: 36527931
Lab Anim (NY). 2017 Mar 22;46(4):167-172
pubmed: 28328880
PLoS One. 2017 Mar 22;12(3):e0174070
pubmed: 28328941
Transplantation. 2010 Feb 15;89(3):353-60
pubmed: 20145528
N Engl J Med. 2008 Feb 21;358(8):811-7
pubmed: 18287603
Sci Rep. 2016 May 27;6:26827
pubmed: 27230536
Sci Adv. 2022 Jan 21;8(3):eabj5908
pubmed: 35044825
Gastroenterology. 2018 Feb;154(3):663-674.e7
pubmed: 29277559
Transpl Immunol. 2022 Feb;70:101517
pubmed: 34923120
Microorganisms. 2020 Sep 15;8(9):
pubmed: 32942608
J Hepatol. 2019 Jan;70(1):206-209
pubmed: 30563687
J Virol. 2014 Aug;88(15):8696-705
pubmed: 24850742
J Virol. 2019 Feb 5;93(4):
pubmed: 30463960
Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):6914-6923
pubmed: 28630341
Clin Infect Dis. 2020 Aug 22;71(5):1204-1211
pubmed: 31793638
Hepatology. 2022 Sep;76(3):788-802
pubmed: 35278241
Hepatology. 2017 Jun;65(6):1823-1839
pubmed: 28195391
Gut. 2020 May;69(5):901-910
pubmed: 31727684
Front Microbiol. 2020 Apr 15;11:656
pubmed: 32351484
Sci Rep. 2016 Jun 08;6:27597
pubmed: 27270888
J Virol. 2014 Oct;88(20):11924-32
pubmed: 25100852
Am J Transplant. 2013 Jul;13(7):1935-6
pubmed: 23659713